Year archive

Akeso, Inc. — 2024 filings

All 54 regulatory filings released by Akeso, Inc. (9926) in 2024, sourced directly from the official regulator.

54 Filings

2024 Period

2024 filings (54)

Filing	Released	Lang
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2024 Regulatory Filings	2024-12-04	English
VOLUNTARY ANNOUNCEMENT - THE INCLUSION IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST OF CADONILIMAB AND IVONESCIMAB Regulatory Filings	2024-11-28	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2024 Regulatory Filings	2024-11-04	English
Next Day Disclosure Return Regulatory Filings	2024-10-21	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2024-10-21	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2024-10-13	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2024 Regulatory Filings	2024-10-03	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE NEW DRUG APPLICATION OF (EBRONUCIMAB, PCSK9) Regulatory Filings	2024-09-30	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA OF (CADONILIMAB, PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR GASTRIC CANCER Regulatory Filings	2024-09-30	English
2024 INTERIM REPORT Regulatory Filings	2024-09-30	English
VOLUNTARY ANNOUNCEMENT - PFS HR 0.51, MPFS 11.14 MONTHS IVONESCIMAB MONOTHERAPY VS PEMBROLIZUMAB AS 1L TREATMENT OF PD-L1 POSITIVE NSCLC (AK112-303/HARMORNI-2) PHASE III RESULTS PUBLISHED AT 2024 Regulatory Filings	2024-09-09	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2024 Regulatory Filings	2024-09-03	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 Regulatory Filings	2024-08-28	English
DATE OF BOARD MEETING Regulatory Filings	2024-08-16	English
VOLUNTARY ANNOUNCEMENT - AK112-303/HARMONI-2 WAS ACCEPTED AS LBA OF 2024 WCLC PRESIDENTIAL SYMPOSIUM ORAL PRESENTATION Regulatory Filings	2024-08-12	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2024 Regulatory Filings	2024-08-05	English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR IVONESCIMAB (PD-1/VEGF) MONOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION Regulatory Filings	2024-07-30	English
APPOINTMENT OF CHIEF FINANCIAL OFFICER Regulatory Filings	2024-07-22	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2024 Regulatory Filings	2024-07-05	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Regulatory Filings	2024-07-01	English
CHANGE OF DIRECTORS Regulatory Filings	2024-07-01	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON SUNDAY, JUNE 30, 2024 Regulatory Filings	2024-07-01	English
2021 RSU SCHEME Regulatory Filings	2024-06-14	English
SHARE OPTION SCHEME Regulatory Filings	2024-06-14	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON SUNDAY, JUNE 30, 2024 Regulatory Filings	2024-06-06	English
NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2024-06-06	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; PROPOSED AMENDMENTS Regulatory Filings	2024-06-06	English
(I) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME AND THE SHARE OPTION SCHEME; AND (II) TERMINATION OF THE PRE-IPO RSU SCHEME Regulatory Filings	2024-06-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2024 Regulatory Filings	2024-06-05	English
VOLUNTARY ANNOUNCEMENT - AMENDMENT TO THE LICENSE AGREEMENT FOR IVONESCIMAB (PD-1/VEGF) WITH SUMMIT THERAPEUTICS INC. Regulatory Filings	2024-06-03	English
VOLUNTARY ANNOUNCEMENT - AK112-303 REACHED PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL SUPERIORITY AS FIRST LINE MONOTHERAPY FOR Regulatory Filings	2024-05-31	English
VOLUNTARY ANNOUNCEMENT (IVONESCIMAB INJECTION) OBTAINED NMPA'S MARKETING APPROVAL IN CHINA Regulatory Filings	2024-05-24	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2024 Regulatory Filings	2024-05-07	English
Notification Letter and Reply Form to Non-registered Holders - Notice of Publication of 2023 Annual Report Regulatory Filings	2024-04-29	English
Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of 2023 Annual Report Regulatory Filings	2024-04-29	English
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Regulatory Filings	2024-04-29	English
2023 ANNUAL REPORT Regulatory Filings	2024-04-29	English
EXCEEDED 2023 ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS MASTER MATERIALS AND SERVICES PROCUREMENT AGREEMENT WITH CHIA TAI TIANQING IN RELATION TO CLINICAL TRIAL OF PENPULIMAB (PD-1 MONOCLONAL Regulatory Filings	2024-04-28	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER Regulatory Filings	2024-04-24	English
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-04-08	English
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-04-08	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024 Regulatory Filings	2024-04-05	English
Next Day Disclosure Return Regulatory Filings	2024-03-28	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2024-03-28	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2024-03-21	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 Regulatory Filings	2024-03-18	English
DATE OF BOARD MEETING Regulatory Filings	2024-03-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024 Regulatory Filings	2024-03-05	English
INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT Regulatory Filings	2024-03-05	English
CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS Regulatory Filings	2024-03-04	English
CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS Regulatory Filings	2024-02-09	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024 Regulatory Filings	2024-02-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023 Regulatory Filings	2024-01-05	English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR GASTRIC CANCER Regulatory Filings	2024-01-05	English